Jakafi 10 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FQWH6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $37,094
Award facts
- Contract value 100% obligated
- $37,094.43 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $37,094.43 to DMS Pharmaceutical Group Inc. for Jakafi 10 mg tablets (60-count units) on December 30, 2025, with an ultimate completion date of December 31, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for Department of Defense medical facilities.
Under the PPV-G GEN V contract vehicle, which was awarded to DMS Pharmaceutical Group on November 13, 2025 with a ceiling value of $499,999,999 and a completion date of December 31, 2036, the Defense Logistics Agency issues firm fixed-price delivery orders for a comprehensive range of pharmaceutical products including branded and generic prescription medications, biologics, and medical consumables. This delivery order for Jakafi represents one of numerous orders issued under the prime vendor contract to support recurring medical supply needs of military healthcare facilities worldwide. DMS Pharmaceutical Group has established substantial performance across multiple therapeutic categories and product lines since being awarded the PPV-G GEN V prime vendor contract, positioning the company as a critical pharmaceutical supplier for Department of Defense global healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FQWH6?
SPE2DR26FQWH6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 30, 2025.
How much is contract SPE2DR26FQWH6 worth?
The government has obligated $37,094 on SPE2DR26FQWH6.
Is contract SPE2DR26FQWH6 an order under another contract?
Yes. SPE2DR26FQWH6 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWH6 competed?
The extent of competition for SPE2DR26FQWH6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award